INTENSITY THERAPEUTICS, INC. cotiza a 3.55 USD y tiene una capitalización bursátil de $12M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue…
| Periodo | 2026-05 | 2025-11 | 2025-08 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.96 | $-1.50 | $-3.25 | — |
| Estimado | $-1.09 | $-1.50 | $-4.50 | $-0.18 |
| Sorpresa | +11.9% | +0.0% | +27.8% | — |
| Métrica | INTS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -97.7% | -40.4% | -57.3% |
| ROA | -82.3% | -32.0% | -50.3% |
| Current Ratio | 5.92 | 2.84 | +3.08 |
| Debt / Equity | — | 0.28 | — |